U.S. markets closed

Mustang Bio, Inc. (MBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4600+0.0600 (+1.76%)
At close: 1:00PM EST

Mustang Bio, Inc.

377 Plantation Street
1st floor
Worcester, MA 01605
United States
781 652 4500
http://www.mustangbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. WeissExec. Chairman60kN/A1966
Dr. Manuel LitchmanPres, CEO & Director519.6kN/A1954
Mr. Brian K. Achenbach M.B.A.Sr. VP of Fin. & Corp. Controller302.36kN/A1965
Dr. Knut NissChief Technology OfficerN/AN/AN/A
Ms. Debra Manning SPHRVP of HRN/AN/AN/A
Dr. Martina A. Sersch M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Ms. Lynn E. BaylessHead of Regulatory AffairsN/AN/AN/A
Ms. Robyn M. HunterCorp. Sec.N/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Corporate Governance

Mustang Bio, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.